Creative Biomart Blog

Sat, 2019/01/12

Embo Mol Med: Identification of a Novel Therapeutic Target for the Chronic Inflammatory Colon Cancer

Recently, a research report published in the international magazine EMBO Molecular Medicine, scientists from the Barcelona Institute of Biomedical Research discovered a new mechanism that can promote inflammation-related colon cancer, and the mechanism also can help develop new cancer therapies as a new target. More than 1 million people worldwide are diagnosed with colon cancer each year. Although many cases are spontaneous, chronic inflammation is also a major cause of colon cancer. Researcher Angel R. Nebreda said that the capability of myeloid cells enhance tumorigenesis may be determin

Thu, 2019/01/10

What’s the Future of Biosimilar Drugs Development?

In general, biosimilars are generic products of biopharmaceuticals. Different from generics, they are “similar” and therefore require approval procedures similar to new branded drugs. Although there are about 25 approved biosimilars in Europe, they did not receive the same treatment in the United States. Despite 11 drugs are approved in the United States, only about 3 kinds can be utilized in patients for branded pharmaceutical companies are using commercial strategies to prevent biosimilar drugs from competing for their current high-priced biopharmaceuticals. The US FDA launched a biosi

Wed, 2019/01/09

Dna2 Deficiency May Result in DNA Insertions at Chromosomal Breaks

Cells have many mechanisms to protect genomic integrity, including the process of repairing errors that may occur during DNA replication. The Dna2 nuclease is involved in DNA repair, but little is known about its effect on chromosomal instability. In a new study, researchers from several research institutions, including Baylor College of Medicine, revealed that when Dna2 is missing, smaller DNA fragments jump from the entire genome to the chromosomal breaks. This new mechanism may explain similar events that are often observed during cancer or antibody diversification. The study was published

Wed, 2018/12/05

JCI: STAT3 Inhibitor May Provide New Hope for Leukemia Treatment

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are malignant hematopoietic stem cell disorders, and abnormal stem cell populations in hematopoietic stem and progenitor cells can cause disease. Traditional treatments to date can not completely eliminate these abnormal hematopoietic stem cells associated with the disease. Recently, researchers from the Albert Einstein College of Medicine have discovered a prognosis molecule that predicts both MDS and AML. Furthermore, an antisense oligonucleotide targeting the disease-causing molecule was identified to have a potential therap

Tue, 2018/12/04

New Drug Targets That Are Expected to Treat Malignant Cancer Discovered

Recently, scientists from the Dana-Farber Cancer Institute have discovered new drug targets for two malignant cancers. It is expected to develop new therapies for the treatment of synovial sarcoma and malignant rods-shaped tumors. Related research result was published in the Nature Cell Biology. The researchers say that these two cancers depend on a new molecular called ncBAF, which plays a key role in regulating gene activity, consisting of multiple specific protein subunits. Biologically or chemically inactivating components of ncBAF may specifically impair proliferation of synovial sarco

Mon, 2018/11/19

Herpes Virus Is One of the Causes of Alzheimer's Disease!

Alzheimer's disease is one of the most common forms of dementia. More than 30 million people worldwide suffer from Alzheimer's disease. Unfortunately, there is currently no cure for the disease, only drugs that relieve the symptoms of the patient; in a recently published dissertation, the author (Professor Ruth Itzhaki of the University of Manchester) proposed a new method for the treatment of Alzheimer's disease. The researchers pointed out that some studies have shown that herpes virus may be one of the reasons inducing Alzheimer's disease. Therefore, effective and safe antiviral drugs may b

Wed, 2018/11/14

Progress in HIV Research in October 2018 (II)

(...Continued) JCI: Infectious HIV is not present in liver macrophages of HIV-infected patients receiving treatment doi:10.1172/JCI121678 In a new study, researchers from Johns Hopkins University and Los Alamos National Laboratory determined whether liver macrophages are infectious HIV-1 virus pools after ART treatment. The real source of the liver tissue samples from nine HIV-1 infected individuals (7 of them were transplanted at Johns Hopkins Hospital). Eight of these nine patients received ART treatment from 8 months to 140 months. The results of the study were published in the J

Wed, 2018/11/14

Progress in HIV Research in October 2018 (I)

Human immunodeficiency virus (HIV), an AIDS (AIDS, acquired immunodeficiency syndrome) virus, is a virus that causes defects in the human immune system. In 1983, HIV was first discovered in the United States. It is a lentivirus that infects cells of the human immune system and is a type of retrovirus. By destroying the body's T lymphocytes, HIV blocks cellular and humoral immune processes, causing the immune system to deficiency, and causing various diseases to spread in the human body and eventually leading to AIDS. Due to the extremely rapid variation of HIV, it is difficult to produce a spe